Mazdutide has no FDA label, so every dose figure here traces back to its published trials rather than a prescribing guideline. Its Phase 2 obesity trial tested once-weekly subcutaneous doses of 3 mg, 4.5 mg, and 6 mg over 24 weeks, and the Phase 3 GLORY-1 trial used 4 mg and 6 mg over 48 weeks with staged escalation.[1][2][3]
Reviewed for accuracy · Last reviewed July 8, 2026Published trials used once-weekly subcutaneous doses with staged escalation. An illustrative low-to-mid schedule from the Phase 2 and GLORY-1 protocols:
A separate Phase 3 trial studied a 9 mg maintenance dose reached with a two-step titration:
A separate Phase 3 trial, GLORY-2, studied a higher 9 mg maintenance dose reached with a two-step titration, which produced the largest reported weight loss but also more gastrointestinal effects. The titration approach below mirrors the stepwise design of these studies: start low and increase gradually so the gut can adjust.
Because mazdutide is investigational outside China, treat these numbers as a description of what was studied, not a recommendation. The data also come largely from Chinese trial populations, which may limit how well they generalize.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.